This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).

This disclosure describes the use of a phosphodiesterase-5 (PDE5) inhibitor to reduce an individual's desire to smoke and/or frequency of smoking. In some embodiments, the PDE5 inhibitor is sildenafil (e.g., Viagra).

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Provided herein are methods of treating cartilage disorders in a subject using a dual CLK/DYRK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, or a combination of a CLK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, and DYRK inhibitor or, pharmaceutically acceptable salt or solvate thereof.

Provided herein are methods of treating cartilage disorders in a subject using a dual CLK/DYRK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, or a combination of a CLK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, and DYRK inhibitor or, pharmaceutically acceptable salt or solvate thereof.

The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., RB1 or another member of the E2F pathway). In addition, the present invention relates to methods of treating an identified patient with a CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either alone or in combination with a second therapeutic agent. In another aspect, the present invention features kits including instructions for treating a patient identified as described herein.

The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., RB1 or another member of the E2F pathway). In addition, the present invention relates to methods of treating an identified patient with a CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either alone or in combination with a second therapeutic agent. In another aspect, the present invention features kits including instructions for treating a patient identified as described herein.

The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy). Patients are identified based on one or more features (e.g., gene copy number or expression level) of certain biomarkers (e.g., RB1 or another member of the E2F pathway). In addition, the present invention relates to methods of treating an identified patient with a CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either alone or in combination with a second therapeutic agent. In another aspect, the present invention features kits including instructions for treating a patient identified as described herein.

The invention describes anti-cancer therapies comprising using an MDM2 inhibitor in combination with a PD-1 antagonist and a LAG-3 antagonist, each as described herein.